# Efficacy of a Prebiotic Galactooligosaccharide to Reduce Metabolic Syndrome Risk Factors in Overweight Adults

> **NCT01004120** · PHASE1,PHASE2 · COMPLETED · sponsor: **Clasado** · enrollment: 48 (actual)

## Conditions studied

- Metabolic Syndrome X

## Interventions

- **DIETARY_SUPPLEMENT:** Bimuno
- **DIETARY_SUPPLEMENT:** Maltodextrin

## Key facts

- **NCT ID:** NCT01004120
- **Lead sponsor:** Clasado
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2011-12
- **Final completion:** 2012-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2016-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01004120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01004120, "Efficacy of a Prebiotic Galactooligosaccharide to Reduce Metabolic Syndrome Risk Factors in Overweight Adults". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01004120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*